Forte Biosciences Inc (FBRX)
NCM · Healthcare · Biotechnology
$76.99
+0.00%
Closing price as of 2026-08-28 · Source: TEK2day Finance
Key Metrics
Market Cap
$1.63B
Shares Outstanding
21.2M
Exchange
NCM
Currency
USD
About Forte Biosciences Inc
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (18.4M) | (24.6M) | (22.4M) | (24.6M) |
| Net Income | (17.7M) | (24.8M) | (22.1M) | (23.3M) |
| Diluted EPS | $-0.99 | N/A | $-1.24 | $-0.98 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (13.9M) | (32.5M) | (36.6M) | (70.7M) |
| Net Income | (13.9M) | (31.5M) | (35.5M) | (69.4M) |
| Diluted EPS | $-20.00 | $-24.92 | $-12.17 | $-4.71 |